Wed Dec 25 00:52:52 UTC 2024: ## Senores Pharmaceuticals IPO Oversubscribed 93 Times, Commands High Grey Market Premium

**Mumbai, India** – Senores Pharmaceuticals Ltd.’s initial public offering (IPO) concluded Tuesday with overwhelming investor interest, exceeding expectations by a significant margin. The IPO, which offered a total of Rs 582.1 crore (approximately $70 million USD) in shares, was subscribed a staggering 93.41 times by the close of the subscription period.

This strong demand surpassed even Day 2’s impressive 13.9 times oversubscription rate. The IPO comprised a fresh issue of Rs 500 crore and an offer for sale of Rs 82.1 crore by promoters Swapnil Jatinbhai Shah, Ashokkumar Vijaysinh Barot, and Sangeeta Mukur Barot. The price band was set between Rs 372 and Rs 391 per share.

The grey market premium (GMP), an unofficial indicator of expected listing price, reached Rs 230 per share by late Tuesday, suggesting a potential listing price of Rs 621—a 58.82% premium over the higher end of the IPO price band. It is crucial to remember that GMP is speculative and not an official price quote.

Senores Pharmaceuticals, a global research-driven pharmaceutical company, plans to use the IPO proceeds for various purposes, including: capital expenditure for a new sterile injection manufacturing facility in Atlanta; repayment of borrowings; funding working capital requirements for its subsidiaries, Havix Group Inc. (Aavis Pharmaceuticals), Senores Pharmaceuticals Inc., and Ratnatris Pharmaceutical Pvt. Ltd.; inorganic growth through acquisitions; and general corporate purposes.

The company focuses on developing and manufacturing generic pharmaceutical products, primarily for regulated markets in the US, Canada, and the UK, as well as emerging markets in 43 countries. As of March 31, they had approvals for 19 abbreviated new drug applications. They also operate a critical care injectables business in India and manufacture active pharmaceutical ingredients (APIs).

While the high oversubscription rate and significant GMP indicate strong investor confidence, potential investors are cautioned to consult with financial advisors and thoroughly review the red herring prospectus before making any investment decisions, as IPOs are subject to market risks. The strong demand for Senores Pharmaceuticals’ IPO signals a positive outlook for the company and the pharmaceutical sector.

Read More